课题基金 / 基金详情

Adjuvant gene therapy for pancreatic cancer using hybrid type liposome vector

Adjuvant gene therapy for pancreatic cancer using hybrid type liposome vector
使用混合型脂质体载体进行胰腺癌的辅助基因治疗
批准号:
10470251
负责人:
SUNAMURA Makoto
金额:
$7.87万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 2000

项目摘要

项目成果

SUNAMURA Makoto的其他基金

相似基金

相关文献

中文摘要
翻译
E.大肠杆菌尿嘧啶磷酸核糖基转移酶(UPRT)催化5-FU合成FUMP,导致FdUMP产量增加,其通过抑制胸苷酸合成功能诱导细胞毒性作用。我们构建了表达UPRT的突变型腺病毒载体(AxElAdB-UPRT),该载体在无p53功能的肿瘤细胞中优先复制。使用腺病毒载体(Ax-UPRT和Ax-lacZ)将UPRT或lacZ基因转染缺乏p53功能的胰腺癌细胞,并在含有不同浓度的5-FU的培养基中培养。使用腹膜内播散的ASPC-1肿瘤小鼠模型评价AxE 1AdB-UPRT/5-FU治疗的治疗优势。在肿瘤接种后10天通过腹膜内注射载体治疗小鼠,随后给予5-FU(10 mg/Kg)7天。4周后处死小鼠并测量肿瘤重量。5株胰腺癌细胞对5-FU的敏感性显著提高(7.1 ...更多信息 -72倍)。Ax-UPRT/5-FU组瘤重(0.24 g)较Ax-lacZ/5-FU组(0.56 g)显著降低(P<0.001)。AxE 1AdB-UPRT/5-FU组细胞凋亡率明显降低(0.15g)。(P=0.042 vs Ax-UPRT/5-FU组)。FdUMP对消化道的不良反应也因5-FU剂量的减少而减轻。肿瘤的生长和转移能力依赖于血管生成。血管生成是肿瘤从一个小的,无害的突变细胞簇转变为一个大的,恶性生长的关键步骤之一,能够扩散到整个身体的其他器官。我们转染Panc-1细胞与可溶性VEGF受体(flt 1)和作为对照与lacZ基因使用腺病毒载体Adsflt和AdlacZ,分别。从植入后第8天到第12天,每天将Adsflt或AdlacZ(3.5 × 10^7 PFU)或100 μl PBS直接注射到肿瘤中。此外,我们将野生型Panc-1及其转染子植入背部皮褶腔中,并使用体内显微镜系统监测肿瘤血管生成。与HUVEC培养基中的水平(8 pg/ml)相比,在所有细胞系中条件培养基中的VEGF水平(平均值,1969 pg/ml ; Panc-1,980 pg/ml)更高。RT-PCR和北方印迹分析检测VEGF mRNA在所有细胞系中的表达,并通过DNA测序证实。Adsflt感染细胞的肿瘤生长速度低于AdlacZ组和未处理组,差异有统计学意义。野生型Panc-1和LacZ转染子植入促进了如在皮褶腔室中观察到的强肿瘤血管生成,而可溶性flt-1转染子未能发挥这种作用。少
英文摘要
E. coli uracil phosphoribosyltransferase (UPRT) catalyzes the synthesis of FUMP from 5-FU, resulting in increased production of FdUMP, which induces cytotoxic effect by inhibiting the function of thymidylate synthesis. We constructeded UPRT expressing mutant adenovirus vector (AxElAdB-UPRT) that replicates preferentially in tumor cells without p53 function. Pancreatic cancer cells lacking p53 function were transfected with either UPRT or lacZ gene using adenovirus vectors (Ax-UPRT and Ax-lacZ) and cultured in medium containing various concentration of 5-FU. Therapeutic advantage of AxE1AdB-UPRT/5-FU treatment was evaluated using intraperitoneal disseminated ASPC-1 tumor mice model. The mice were treated with intraperitoneal injection of vectors 10 days after tumor inoculation, followed by the administration of 5-FU(10 mg/Kg) for 7days. Mice were sacrificed and tumor weight was measured 4 weeks later. The sensitivity against 5-FU of 5 pancreatic cancer cells increased significantly (7.1 … More -72 fold) after the transfection of UPRT gene. Tumor weight in Ax-UPRT/5-FU group (0.24 g) was significantly reduced as compared to Ax-lacZ/5-FU group (0.56 g) (P<0.001). Furthermore, that of AxElAdB-UPRT/5-FU group was significantly decreased (0.15 g).(P=0.042 vs Ax-UPRT/5-FU group). Furthermore, the adverse effect of FdUMP on alimentary tract was diminished because of the decreasd dosage of 5-FU.The growth of a tumor and its ability to metastasize is angiogenesis-dependent. Angiogenesis is one of the crucial steps in tumor's transition from a small, harmless cluster of mutated cells to a large, malignant growth, capable of spreading to other organs throughout the body soluble. We transfected Panc-1 cells with soluble VEGF receptor (flt1) and as control with the lacZ gene using the adenovirus vectors Adsflt and AdlacZ, respectively. Adsflt or AdlacZ (3.5X10^7 PFU) or 100 μl of PBS were injected directly into tumors daily from day 8 through day 12 after the implantation. Furthermore, we implanted in dorsal skinfold chamber the wild-type Panc-1 and its transfectants and monitored the tumor angipgenesis using in vivo microscope system. VEGF levels in conditioned media were higher in all cell lines (mean, 1969 pg/ml ; Panc-1, 980 pg/ml), compared to the level in media of HUVEC (8 pg/ml). Expression of VEGF mRNA was detected in the all cell lines by RT-PCR and Northern blot analysis and it was confirmed by DNA sequencing. Tumor growth rate of Adsflt-infected cells was lower than those of AdlacZ group and no treatment group, and the difference was statistically significant. Wild type Panc-1 and the LacZ transfectant implantation prompted strong tumor angiogenesis as observed in skinfold chamber, whereas soluble flt-1 transfectants failed to exert such an effect. Less
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
Sunamura M: "The anti-angiogenesis effect of IL-12 during early growth of human pancreatic cancer in SCID mice"Pan Creas. 20・3. 227-233 (2000)
Sunamura M:“IL-12 在 SCID 小鼠早期生长过程中的抗血管生成作用”Pan Creas 20・3(2000)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
砂村眞琴: "膵癌に対する遺伝子治療法の開発"日本臨床59:98-103,2001. 59・1. 98-103 (2001)
Makoto Sunamura:“胰腺癌基因治疗的发展”日本临床研究59:98-103,2001 59・1(2001)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Sunamura M., Motoi F., Matsuno S.: "Restricted Replication-Competent Adenovirus : a Novel Strategy for Cancer Gene Therapy"Int J Clin Oncol. 5. 147-152 (2000)
Sunamura M.、Motoi F.、Matsuno S.:“具有限制性复制能力的腺病毒:癌症基因治疗的新策略”Int J Clin Oncol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Sunamura M: "Restricted Replication-Competent Adenovirus : a Novel Strategy for Cancer Gene Therapy"Int J Clin Oncol. 5・7. 147-152 (2000)
Sunamura M:“限制性复制腺病毒:癌症基因治疗的新策略”Int J Clin Oncol 5・7(2000)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 11 条
    Development of new gemcitabine that can overcome acquired gemicitabine resistancy
    • 批准号:
      22591512
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2010
    • 负责人:
      SUNAMURA Makoto
    • 依托单位:
    Resolution of the function of cancer cells and the application for tailor-made therapy using bio-simulation analysis
    • 批准号:
      18390358
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.79万
    • 财政年份:
      2006
    • 负责人:
      SUNAMURA Makoto
    • 依托单位:
    Induction of insulin secreting cell and its application for transplantation
    • 批准号:
      14370346
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.73万
    • 财政年份:
      2002
    • 负责人:
      SUNAMURA Makoto
    • 依托单位:
    Gene therapy for cancer using the gone gun system
    • 批准号:
      09557094
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $7.55万
    • 财政年份:
      1997
    • 负责人:
      SUNAMURA Makoto
    • 依托单位:
    海外基金